5 results
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
Main: To evaluate the safety and effectiveness of the Exhale Drug-Eluting Stent (DES) to improve pulmonary function for homogeneous emphysema subjects with severe hyperinflation, in a prospective, randomized, Sham-controlled, double-blind, multi-…